All Comparisons
Gene Editing Comparison

Ex Vivo vs In Vivo Gene Editing

Gene editing can happen in two fundamentally different ways: ex vivo (removing cells, editing them in a lab, and returning them) or in vivo (delivering editing tools directly into the patient's body). Casgevy, the first FDA-approved CRISPR therapy, uses the ex vivo approach for sickle cell disease. Intellia Therapeutics is pioneering the in vivo approach, delivering CRISPR via lipid nanoparticles directly into the liver. Both are clinically validated, but they differ dramatically in complexity, cost, scalability, and the diseases they can treat.

Last updated: March 30, 2026

Ex Vivo Gene Editing

Patient cells (typically hematopoietic stem cells or T-cells) are harvested, gene-edited using CRISPR electroporation or viral vectors in a GMP laboratory, quality-checked for on-target editing and off-target safety, then infused back into the patient after myeloablative conditioning chemotherapy.

In Vivo Gene Editing

CRISPR components (Cas9 mRNA + guide RNA) are encapsulated in lipid nanoparticles and delivered directly into the patient's body via a simple IV infusion, editing cells in their natural location without any cell extraction or chemotherapy conditioning.

Key Specifications

FeatureEx Vivo Gene EditingIn Vivo Gene Editing
Where editing occursGMP laboratory (outside the body)Inside the patient's body (in situ)
FDA-approved productsCasgevy (CRISPR Therapeutics/Vertex, Dec 2023)None yet — Intellia lonvo-z BLA target H2 2026
Delivery methodElectroporation of CRISPR RNP into harvested cellsLNP-encapsulated Cas9 mRNA + guide RNA via IV infusion
Conditioning requiredYes — myeloablative busulfan (for HSPC therapies)No — simple outpatient IV infusion
Treatment timeline6-9 months from cell harvest to infusionSingle 25-minute to 1-hour IV infusion
Cost per patient$2.2M (Casgevy) to $3.1M (Lyfgenia)
ManufacturingIndividualized per patient — not scalable batch productionBatch production — one lot treats many patients
Off-target verificationPre-infusion sequencing and QCPost-treatment monitoring only (no pre-verification)
Treatable organsBlood (HSPCs), immune cells (T-cells)Liver (current), CNS/lung/muscle (in development)
Re-dosingPossible (new cell harvest) but impracticalPotentially possible with LNPs (no anti-vector immunity)
Estimated cost per patientPotentially $500K-$1.5M (lower than ex vivo due to scalable manufacturing)

Ex Vivo Gene Editing

Advantages

  • FDA-approved: Casgevy (CRISPR) approved Dec 2023 for SCD and thalassemia — $116M revenue, ~165 patients in 2025
  • Edits verified before infusion: sequencing confirms on-target editing and screens for off-target events
  • Proven durability: 97% of Casgevy patients free from vaso-occlusive crises at 12+ months
  • Complex multi-gene edits possible: allogeneic CAR-T (zugo-cel) makes 4+ simultaneous edits per cell
  • Applicable to blood disorders, cancers, and immune diseases — large existing clinical infrastructure for cell therapy

Limitations

  • Requires myeloablative conditioning (busulfan chemotherapy) — hospitalization, infertility risk, 1-3% treatment-related mortality
  • Manufacturing takes 4-8 weeks per patient — each batch is individualized and requires GMP facilities
  • Extremely expensive: $2.2M (Casgevy), $3.1M (Lyfgenia) — reimbursement and access barriers globally
  • Limited to accessible cell types — cannot edit liver, brain, heart, lung, or muscle cells ex vivo
  • Patient must be healthy enough to undergo stem cell harvest and conditioning — excludes fragile patients

In Vivo Gene Editing

Advantages

  • Simple IV infusion — no hospitalization, no conditioning chemotherapy, no stem cell harvest required
  • Intellia lonvo-z Phase 3 HAELO enrollment completed in 9 months — 97% of patients attack-free at 3 years
  • Intellia nex-z: 93% TTR protein knockdown sustained 3+ years from a single 25-minute infusion
  • Scalable manufacturing: LNP batches serve many patients vs. individualized ex vivo manufacturing
  • Can reach organs inaccessible ex vivo — currently liver, with CNS, lung, and muscle delivery in development

Limitations

  • No FDA-approved in vivo gene editing therapy yet — lonvo-z BLA target H2 2026, potential approval 2027
  • Cannot verify edits before they happen — editing is irreversible once LNPs reach target cells
  • Currently limited to liver-directed editing via LNP — non-liver organs remain a delivery challenge
  • Intellia's MAGNITUDE trial (nex-z, ATTR-CM) had FDA clinical hold due to safety concerns — now lifted
  • Dose-dependent liver toxicity (ALT elevations) observed at higher doses in clinical trials

The Verdict

Ex vivo and in vivo gene editing are complementary approaches serving different patient populations. Ex vivo editing (Casgevy) is FDA-approved and clinically proven for blood disorders, with the critical advantage of pre-infusion edit verification. But its $2.2M+ cost, 6-9 month timeline, myeloablative conditioning, and limitation to accessible cell types create massive barriers to global access — fewer than 200 patients have been treated in two years. In vivo editing (Intellia's lonvo-z and nex-z) promises to transform gene editing from a complex transplant procedure into a simple IV infusion, with scalable manufacturing that could dramatically lower costs. The 3-year clinical data is extraordinary: 97% of lonvo-z patients attack-free, 93% TTR knockdown with nex-z. If lonvo-z is approved in 2027, it would mark a paradigm shift — gene editing accessible to any hospital with an infusion center, not just specialized transplant centers. The future belongs to in vivo delivery, but ex vivo editing remains essential for blood disorders and will likely persist for diseases requiring complex multi-gene edits in immune cells.

More Comparisons